Ocular Therapeutix, Inc. (OCUL)
Pharmaceutical Preparations · market cap $2.2B · as of 2026-10-27
Research and calibrated estimates, not financial advice — verify before acting.
- 2027-01-08 (est.)Phase 3 · OTX-TKIimp 9/10
- 2027-03-15 (est.)Phase 3 · Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24imp 9/10
- 2027-06-12 (est.)PDUFA · Axpaxliimp 8/10
| Asset | Phase | Indication |
|---|---|---|
| OTX-TKI (axitinib implant) | Phase 3 | Neovascular Age-Related Macular Degeneration |
| OTX-TP | Phase 2 | Glaucoma |
| Punctum Plug | Phase 3 | Post Ocular Surgical Inflammation and Pain |
| OTX-CSI | Phase 2 | Dry Eye Disease |
| OTX-DED | Phase 2 | Dry Eye |
| Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24 | Phase 3 | Non-Proliferative Diabetic Retinopathy |
| Ophthalmic Insert | Phase 3 | Open Angle Glaucoma and Ocular Hypertension |
| OTX-TIC low dose Travoprost Intracameral Implant | Phase 2 | Open Angle Glaucoma |
| Dextenza Ophthalmic Insert | Phase 3 | Cataract |
| Travoprost | Phase 3 | Open Angle Glaucoma |
| OTX-DP (Dexamethasone punctum plug) | Phase 2 | Ocular Inflammation and Pain |
| Controlled Insertion | Phase 2 | Dry Eye Syndromes |
| Dexamethasone | Phase 3 | Allergic Conjunctivitis |
| OTX-TKI | Phase 3 | Neovascular Age-related Macular Degeneration |
| OTX-TIC high dose Travoprost Intracameral Implant | Phase 2 | Open Angle Glaucoma |
| Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24 | Phase 3 | Non-Proliferative Diabetic Retinopathy |
Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
- SEC filings — EDGAR filings for OCUL (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 16 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.
